Australia's most trusted
source of pharma news
Posted 15 July 2026 PM
The Sydney-based Viral Vector Manufacturing Facility (VVMF) has signed a letter of intent to collaborate with Melbourne biotech Mirugen on the evaluation and potential development of a gene therapy candidate.
The adeno-associated virus (AAV)-based candidate aims to restore sight for people with Retinitis Pigmentosa, a genetic condition characterised by progressive degeneration of photoreceptors and associated vision loss. The condition affects 1.5 million people worldwide, Mirugen says.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.